List of Zilxi drug patents
Zilxi is owned by Journey.
Zilxi contains Minocycline Hydrochloride.
Zilxi has a total of 8 drug patents out of which 0 drug patents have expired.
Zilxi was authorised for market use on 28 May, 2020.
Zilxi is available in aerosol, foam;topical dosage forms.
Zilxi can be used as treatment of inflammatory lesions of rosacea..
The generics of Zilxi are possible to be released after 01 October, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US10322186 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US10946101 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
| US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
| US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2020
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: AEROSOL, FOAM;TOPICAL
ZILXI family patents
52
United States
5
IB
5
Canada
2
Israel
2
Australia
1
Brazil
1
South Africa
1
Mexico
1
China
1
United Kingdom
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic